DRTS News and Press, Alpha Tau Medical Ltd. From 08/24/23

JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences. ...

2023-08-18 09:14:32 ET More on Alpha Tau Alpha Tau Medical a new buy at HC Wainwright on proprietary radiation therapy Alpha Tau director gives up board seat to take up chief commercial officer role Israeli medtech Alpha Tau stock rallies 31% after dropping 16% in pr...

- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year local recurrence-free survival rate of 77%. - The analysis also showed no grade 3 or higher acute treatment-related toxicities, with approx. 2...

JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor con...

2023-05-23 16:29:37 ET Alpha Tau Medical press release ( NASDAQ: DRTS ): Q1 GAAP EPS of -$0.12 misses by $0.01 . As of March 31, 2023, the Company had cash and cash equivalents, restricted cash and deposits in the amount of $100.5 million, compared to&#x...

- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer , which began enrolling patient s in March - - Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in A...

JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with squamous cell carcinoma of the vul...

The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or systemic toxicity reported in the 10 patients treated in the feasibility and safety study of intratumoral Alpha DaRT for the treatment of recurrent or unresectable skin ...

JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will take part in a ...

2023-04-24 14:08:03 ET HC Wainwright has begun Alpha Tau Medical ( NASDAQ: DRTS ) with a buy rating saying that the company's proprietary diffusing alpha-emitting radiation therapy (DaRT) technology is differentiated in treating solid tumors. The firm set a price target of $...